# Luye Pharma Group

Source: https://onco.cc/companies/luye-pharma/  
OnCo record `luye-pharma` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Luye Pharma is a Chinese pharmaceutical group, listed in Hong Kong, whose oncology business rests on paclitaxel liposome (Lipusu) and other reformulated cancer medicines.

## Summary

Luye Pharma Group, based in Yantai in Shandong and listed on the Hong Kong stock exchange, develops and sells medicines in oncology, the central nervous system and cardiovascular disease, with a focus on new formulations and long-acting delivery. Its best-known cancer product is Lipusu, a liposomal formulation of paclitaxel widely used in China, and it runs phase 3 trials of reformulated chemotherapy and targeted agents. OnCo records it as a registry sponsor of phase 3 cancer trials.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Luye Pharma Group Ltd.; Luye Pharma; 绿叶制药
- Tags: ctgov-sponsor
- HQ: Yantai
- Type: pharma
- Website: https://www.luye.cn

## Sources

- Official website: https://www.luye.cn
- ClinicalTrials.gov: trials led by Luye Pharma: https://clinicaltrials.gov/search?lead=Luye%20Pharma
- Wikipedia: https://en.wikipedia.org/wiki/Luye_Pharma_Group

## Connected records

- fronts: [Chemotherapy](https://onco.cc/fronts/chemotherapy/)
- drugs: [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/)

---
JSON: https://onco.cc/api/v1/entities/luye-pharma.json